Allogeneic mesenchymal stem cells (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 47 | Buerger disease | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03056742 (ClinicalTrials.gov) | February 20, 2017 | 23/1/2017 | A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease | A Single Arm, Open Label, Multicentric, Clinical Study Assessing the Efficacy and Safety of Stempeucel® (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With CLI Due to Buerger's Disease | Critical Limb Ischemia Due to Buerger's Disease | Biological: Stempeucel(R) | Stempeutics Research Pvt Ltd | NULL | Withdrawn | 18 Years | 65 Years | All | 0 | Phase 2 | India |
| 2 | NCT01484574 (ClinicalTrials.gov) | January 2012 | 27/11/2011 | A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease | A Non-randomized, Open Label, Multicentric, Dose Ranging , Phase II Study Assessing the Efficacy and Safety of Intramuscular Administration of Stempeucel - CLI™ (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With Critical Limb Ischemia Due to Buerger's Disease | Critical Limb Ischemia;Buerger's Disease | Biological: Allogeneic Mesenchymal Stem Cells | Stempeutics Research Pvt Ltd | NULL | Completed | 18 Years | 65 Years | Both | 90 | Phase 2 | India |